Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Frontiers in Metabolomics for Cancer Research

Draft Agenda

Monday, October 24, 2005
7:30 - 8:00 amRegistration
Session I: Opening Remarks and Welcome
8:00 - 8:15 amWelcoming RemarksPeter Greenwald, Director
Division of Cancer Prevention
National Cancer Institute
Sudhir Srivastava, Chief
Cancer Biomarkers Research Group
John Milner, Chief
Nutritional Sciences Research Group
8:15 - 8:20 amSetting the StagePadma Maruvada and Young Kim
Division of Cancer Prevention
National Cancer Institute
Session II: Overview of Metabolomics
Objective: This session will compare and contrast the evolution of metabolomics, including its definitions, from its predecessors or counterparts and discuss convergences and divergences
8:20 - 8:50 amWhat Is Metabonomics?Julian Griffin
Session II: Methodological and Technological Issues and Concerns (Moderator: Sharon Ross)
Objective: This session will describe prevailing technologies, including those with dual purposes, reagents, and instrumentations, required infrastructures, etc
8:50 - 9:20 amState-of-the Art Technologies on MetabolomicsStephen Brown
9:20 - 9:30 amDiscussion
9:30 am - 10:00 amPathway Discovery Through the Association of Metabolomics and Mass Isotopomer AnalysisHenri Brunengraber
10:00 - 10:10 amDiscussion
10:10 - 10:25 amMorning Break
10:25 - 10:55 amEvolutionary Optimization in MetabolomicsDouglas Kell
10:55 - 11:05 amDiscussion
11:05 - 11:35 amGroup DiscussionDouglas Burrin, Moderator
Session III: Use of Metabolomics for Cancer Research (Moderator: Paul Wagner)
Objective: To identify issues on the application of metabolomics in cancer research
11:35 - 12:05 pmA Crossroad to Tumor Metabolome: Tumor M2 Pyruvate KinaseSybille Mazurek
12:05 - 12:15 pmDiscussion
12:15 - 1:15 pmLunch (on your own)
1:15 - 1:45 pmMetabolomics by Magnetic Resonance: From Molecules to ManJohn Griffiths
1:45 - 1:55 pmDiscussion
1:55 - 2:25 pmMetabolomic Profiling of Human Cancer With Ex Vivo Tissue MR SpectroscopyLeo Cheng
2:25 - 2:35 pmDiscussion
2:35 - 3:05 pmGroup DiscussionSudhir Srivastava, Moderator
3:05 - 3:20 pmAfternoon Break
Session IV: Impact of Cancer Modifiers on Metabolic Profiling (Moderator: Elizabeth Yetley)
Objective: To discuss metabolomic arrays, spectroscopic profiles, and other metabolites-based phenotyping in relation to its application for patients, stratification for responders and non-responders to dietary components, drugs, and toxic agents
3:20 - 3:50 pmDynamics of Glucose Metabolism and CancerPaul Lee
3:50 - 4:00 pmDiscussion
4:00 - 4:30 pmLipidomic Profiling Eicosanoid Changes in CarcinogenesisEdward Dennis
4:30 - 4:40 pmDiscussion
4:40 - 5:10 pmMetabolic Profiling in Drug Discovery and DevelopmentChristopher Newgard
5:10 - 5:20 pmDiscussion
5:20 - 5:50 pmGroup DiscussionJohn Milner, Moderator
5:50 pmAdjourn

Tuesday, October 25, 2005
Session V: Models for Studying Metabolomic Approaches (Moderator: David Goldstein)
Objective: To identify challenges in application of metabolomics in cancer research
8:30 - 9:00 amAnalysis of Metabolic Phenotype Risto Kauppinen Changes in Response to Therapy in Cancer Animal Models
9:00 - 9:10 amDiscussion
9:10 - 9:40 amOther Models To Understand the Cancer Cell Metabolic FluxZoltan Oltvai
9:40 - 9:50 amDiscussion
9:50 - 10:20 amMetabolomics in the Study of CNS DisordersRima Kaddurah-Daouk
10:20 - 10:30 amDiscussion
10:30 - 11:00 amGroup DiscussionBruce Kristal, Moderator
Session VI: Integration of Metabolomics Into Systems Biology (Moderator: Lee Moore)
Objective: To discuss a systems biology approach to mapping small molecules in metabolic pathways and biochemical networks in relation to phenotypic changes
11:00 - 11:30 amIntegration of all "Omics"Pedro Mendes
11:30 - 11:40 amDiscussion
11:40 - 12:10 pmSystems Approach to CancerMichael Liebman
12:10 - 12:20 pmDiscussion
12:20 - 12:50 pmGroup DiscussionJennifer Couch, Moderator
12:50 - 1:50 pmLunch (on your own)
Session VII: Breakouts
1:50 - 3:10 pmBreakouts I, II, and III
Breakout I: Chair: Lance Liotta
Metabolomics vs Other Omics Co-Chair: Samir Hanash
  • What information can metabolomics provide that genomics and/or proteomics may not be able to address?
  • Can metabolic profiling identify individuals who will and who will not get the benefit from treatments with either drugs or dietary components?
  • Can a metabolomics approach serve as a functional annotation that links to the systems biology?

Breakout II: Chair: Bruce Kristal
Application of Metabolomics in Understanding Tumor Cell Behavior
Co-Chair: Gil Omenn
  • What are the key metabolites relevant to tumor cell behavior that should be measured quantitatively in cancer research?
  • Which fluids, cells and/or tissues should be sampled for the examination?
  • Can metabolomic approaches be used to discover and further develop metabolic biomarkers that are distinct in tumor cell environment or in pre-cancerous tissues?

Breakout III: Chair: Henri Brunengraber
Evaluation of Technologies Co-Chair: Alan Kleinfeld
  • What are the strengths and weaknesses of the most commonly used metabolomics technologies?
  • Which bioinformatics tools can be used for the metabolomics data analysis?
  • How can imaging be used to detect metabolites in cells or organs?
Session VIII: Reports on Breakouts
3:10 - 3:20 pmBreakout ILance Liotta
3:20 - 3:30 pmBreakout II Bruce Kristal
3:30 - 3:40 pmBreakout III Henri Brunengraber
3:40 - 3:50 pmFuture DirectionsYoung Kim and Padma Maruvada
3:50 pmAdjourn


Back to top